Clin Exp Vaccine Res.  2013 Jan;2(1):19-25.

The present and future of rabies vaccine in animals

• Yang DK
• Kim HH
• Lee KW
• Song JY

Abstract

An effective strategy for preventing rabies consists of controlling rabies in the host reservoir with vaccination. Rabies vaccine has proven to be the most effective weapon for coping with this fatal viral zoonotic disease of warm-blooded animals, including human. Natural rabies infection of an individual is always associated with exposure to rabid animals, and the duration of clinical signs can vary from days to months. The incubation period for the disease depends on the site of the bite, severity of injury, and the amount of infecting virus at the time of exposure. The mortality of untreated cases in humans is 100%. Over the last 100 years, various rabies vaccines have been developed and used to prevent or control rabies in animals, such as modified live vaccine, inactivated rabies vaccine, and oral modified live vaccine. These have proved safe and efficacious worldwide. New-generation rabies vaccines, including recombinant rabies virus-based vaccines, vectored vaccines, DNA-based vaccines, and plant vaccines, have been explored to overcome the limitations of conventional rabies vaccines. This article discusses current and next-generation rabies vaccines in animals.

Keyword

Rabies vaccines; Bait vaccine; Vectored vaccine; Plant vaccine

MeSH Terms

Animals
Bites and Stings
Plants
Rabies
Rabies Vaccines
Vaccination
Vaccines
Viruses
Rabies Vaccines
Vaccines

Reference

1. Knipe DM, Howley PM, Griffin DE, et al. Field virology. 2001. Philadelphia: Lippincott Williams & Wilkins;1221–1277.

2. World Health Organization. WHO expert consultation on rabies. WHO technical report series No. 931. 2005. Geneva: World Health Organization.

3. Yang DK, Kim SY, Oh YI, et al. Epidemiological characteristics of rabies in South Korea from January 2004 to March 2011. J Bacteriol Virol. 2011. 41:165–171.

4. Kayali U, Mindekem R, Hutton G, Ndoutamia AG, Zinsstag J. Cost-description of a pilot parenteral vaccination campaign against rabies in dogs in N'Djamena, Chad. Trop Med Int Health. 2006. 11:1058–1065.

5. Nyberg M, Kulonen K, Neuvonen E, Ek-Kommonen C, Nuorgam M, Westerling B. An epidemic of sylvatic rabies in Finland: descriptive epidemiology and results of oral vaccination. Acta Vet Scand. 1992. 33:43–57.

6. Yang DK, Oh YI, Cho SD, et al. Molecular identification of the vaccine strain from the inactivated rabies vaccine. J Bacteriol Virol. 2011. 41:47–54.

7. Faber M, Dietzschold B, Li J. Immunogenicity and safety of recombinant rabies viruses used for oral vaccination of stray dogs and wildlife. Zoonoses Public Health. 2009. 56:262–269.

8. Fenje P. Propagation of rabies virus in cultures of hamster kidney cells. Can J Microbiol. 1960. 6:479–484.

9. Fenje P, Pinteric L. Potentiation of tissue culture rabies vaccine by adjuvants. Am J Public Health Nations Health. 1966. 56:2106–2113.

10. Kwon YB, Kim YH, Lim YM. Studies on the production of rabies live vaccine. I. Biological properties of the experimentally produced tissue culture attenuated live vaccine. Res Rep Off Rural Dev. 1981. 23:125–135.

11. Kwon YB, Kim DH, Kim YH. Studies on the production of rabies live vaccine. II. Field application of tissue culture attenuated rabies live vaccine. Res Rep Off Rural Dev. 1982. 24:87–92.

12. Rupprecht CE, Dietzschold B, Campbell JB, Charlton KM, Koprowski H. Consideration of inactivated rabies vaccines as oral immunogens of wild carnivores. J Wildl Dis. 1992. 28:629–635.

13. Roumiantzeff M. The present status of rabies vaccine development and clinical experience with rabies vaccine. Southeast Asian J Trop Med Public Health. 1988. 19:549–561.

14. Chavali SR, Barton LD, Campbell JB. Immunopotentiation by orally-administered Quillaja saponins: effects in mice vaccinated intraperitoneally against rabies. Clin Exp Immunol. 1988. 74:339–343.

15. Baer GM, Abelseth MK, Debbie JG. Oral vaccination of foxes against rabies. Am J Epidemiol. 1971. 93:487–490.

16. Muller TF, Schuster P, Vos AC, Selhorst T, Wenzel UD, Neubert AM. Effect of maternal immunity on the immune response to oral vaccination against rabies in young foxes. Am J Vet Res. 2001. 62:1154–1158.

17. Le Blois H, Tuffereau C, Blancou J, Artois M, Aubert A, Flamand A. Oral immunization of foxes with avirulent rabies virus mutants. Vet Microbiol. 1990. 23:259–266.

18. Cliquet F, Gurbuxani JP, Pradhan HK, et al. The safety and efficacy of the oral rabies vaccine SAG2 in Indian stray dogs. Vaccine. 2007. 25:3409–3418.

19. Wiktor TJ, Macfarlan RI, Reagan KJ, et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A. 1984. 81:7194–7198.

20. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J. 1994. 13:4195–4203.

21. Tuffereau C, Leblois H, Benejean J, Coulon P, Lafay F, Flamand A. Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology. 1989. 172:206–212.

22. Pulmanausahakul R, Faber M, Morimoto K, et al. Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. J Virol. 2001. 75:10800–10807.

23. Wu X, Franka R, Svoboda P, Pohl J, Rupprecht CE. Development of combined vaccines for rabies and immunocontraception. Vaccine. 2009. 27:7202–7209.

24. Weyer J, Rupprecht CE, Nel LH. Poxvirus-vectored vaccines for rabies: a review. Vaccine. 2009. 27:7198–7201.

25. Poulet H, Minke J, Pardo MC, Juillard V, Nordgren B, Audonnet JC. Development and registration of recombinant veterinary vaccines: the example of the canarypox vector platform. Vaccine. 2007. 25:5606–5612.

26. Cadoz M, Strady A, Meignier B, et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 1992. 339:1429–1432.

27. Wang Y, Xiang Z, Pasquini S, Ertl HC. The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus. J Virol. 1997. 71:3677–3683.

28. Tims T, Briggs DJ, Davis RD, et al. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine. 2000. 18:2804–2807.

29. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol. 2003. 77:10780–10789.

30. Zhang S, Liu Y, Fooks AR, Zhang F, Hu R. Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies. Vaccine. 2008. 26:345–350.

31. Fehlner-Gardiner C, Rudd R, Donovan D, Slate D, Kempf L, Badcock J. Comparing ONRAB(R) AND RABORAL V-RG(R) oral rabies vaccine field performance in raccoons and striped skunks, New Brunswick, Canada, and Maine, USA. J Wildl Dis. 2012. 48:157–167.

32. Dhama K, Mahendran M, Gupta PK, Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet Res Commun. 2008. 32:341–356.

33. Lodmell DL, Parnell MJ, Bailey JR, Ewalt LC, Hanlon CA. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine. 2001. 20:838–844.

34. Yusibov V, Hooper DC, Spitsin SV, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine. 2002. 20:3155–3164.

35. Loza-Rubio E, Rojas-Anaya E, Lopez J, Olivera-Flores MT, Gomez-Lim M, Tapia-Perez G. Induction of a protective immune response to rabies virus in sheep after oral immunization with transgenic maize, expressing the rabies virus glycoprotein. Vaccine. 2012. 30:5551–5556.

36. McGarvey PB, Hammond J, Dienelt MM, et al. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology (N Y). 1995. 13:1484–1487.

37. Rojas-Anaya E, Loza-Rubio E, Olivera-Flores MT, Gomez-Lim M. Expression of rabies virus G protein in carrots (Daucus carota). Transgenic Res. 2009. 18:911–919.